Cerenome is trading at $0.79, down 39.22%, with no clear same-direction catalyst identified.
- On November 4, Cerenome announced an Aetna in-network agreement, adding about 26 million members and bringing contracted coverage to approximately 190 million lives. Available reporting does not connect the news to the decline.
- Major U.S. indexes were higher in the supplied market context, so broad market weakness does not explain the drop.